June 12, 2024
Fluticasone HFA - Update to Preferred Drug List (PDL)
Thank you for your continuing efforts to improve the health outcomes of our members. On January 18, 2024, you were advised that GlaxoSmithKline (GSK) has discontinued manufacturing Flovent HFA and Diskus as of December 31, 2023, and were provided a list of preferred drug alternatives.
Effective April 29, 2024, Fluticasone Propionate HFA has been added to the Statewide PDL for Medicaid patients and is now included as a preferred alternative for children 7 years of age and younger without a prior authorization. **As of 6/19/2024, the Department of Human Services (DHS), has updated the age range for children 12 years of age and younger**.
As a reminder, below is a full list of the preferred drug list alternatives.
Preferred Alternatives |
Arnuity Ellipta |
Asmanex HFA |
Asmanex Twisthaler |
Budesonide 0.25 mg/2 ml, 0.5 mg/2 ml |
Pulmicort Respule |
Pulmicort Flexhaler |
Qvar Redihaler |
Arnuity Ellipta |
Fluticasone HFA |
For the most up-to-date information regarding Jefferson Health Plans’ formularies, please visit our formularies at HPPlans.com/Formulary. For more information, call our Pharmacy department at 215-991-4300 or our Provider Services Helpline at 1-888-991-9023 (Monday to Friday, 9 a.m. to 5:30 p.m.).
Thank you for your cooperation in improving the quality of care you deliver to your patients and our members.